



THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Gentz et al.

Docket No.: PF454P1

Application No.: 09/518,931

Confirmation No.: 7173

Filed: March 3, 2000

Art Unit: 1646

For: Tumor Necrosis Factor Receptors 6 Alpha & 6
Beta

Examiner: E. B. O'Hara

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorney/Agent for Applicants hereby directs the Examiner's attention to references CC, CF-CG, CJ-CX, and CZ-DN listed on the attached Form PTO/SB/08. Copies of reference CF and non-U.S. Patent references CC, CJ-CX, and CZ-DN are enclosed.

Identification of the listed references is not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to take appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

The listed references are presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 C.F.R. § 1.104(a) concerning the Examiner's duty to consider and use any such information. Applicants respectfully request that the Examiner make the listed references of record in the file history of the application, and consider the information contained therein during the prosecution of this application.

Pursuant to 37 C.F.R. § 1.97(c), because this Information Disclosure Statement is being submitted after the mailing date of the first Office Action on the merits, but before the mailing

10/12/2005 JADD01 00000141 083425 09518931


01 FC:1806 180.00 DA

date of a Final Office Action, or a Notice of Allowance under 37 C.F.R. § 1.311, or an action that otherwise closes prosecution, the Patent and Trademark Office will consider this Information Disclosure Statement if it is accompanied by the fee as specified in 37 C.F.R. § 1.17(p).

Accordingly, the Patent & Trademark Office is hereby authorized to charge our Deposit Account No. 08-3425 in the amount of \$180.00 as payment of the required fee, as itemized on the Fee Transmittal Sheet submitted concurrently herewith. The Patent & Trademark Office is also authorized to charge any additional required fee or credit any overpayment in connection with this submission to our Deposit Account No. 08-3425.

Dated: October 11, 2005

Respectfully submitted,

By 

Michele Shannon

Registration No.: 47,075

HUMAN GENOME SCIENCES, INC.


Intellectual Property Dept.

14200 Shady Grove Road

Rockville, Maryland 20850

(301) 354-3930

KKH/MS/ba



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/518,931-Conf. #7173
				Filing Date	March 3, 2000
				First Named Inventor	Reiner L. Gentz
				Art Unit	1646
				Examiner Name	E. B. O'Hara
Sheet	1	of	3	Attorney Docket Number	PF454P1


U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No. ¹	U.S. Patent Document Kind Code ² Number (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	Foreign Patent Document Kind Code ⁵ Office ³ Number ⁴ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	CC	DUESTERHOEFT ET AL., Genbank Accession Number AL157435, 2-15-2000.	

Examiner	Date Considered
----------	-----------------

Examiner Signature	Date Considered
-----------------------	--------------------



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(Use as many sheets as necessary)</p>				Complete if Known	
				Application Number	09/518,931-Conf. #7173
				Filing Date	March 3, 2000
				First Named Inventor	Reiner L. Gentz
				Art Unit	1646
				Examiner Name	E. B. O'Hara
Sheet	2	of	3	Attorney Docket Number	PF454P1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	CF	09/912,293	NOT PUBLISHED	ROSEN et al.	Pages 1-75 (pages 1 & 2 partially redacted); portion of Table 2; and SEQ ID NOS: 29783 and 63238
	CG	6,297,367-B1	10-02-2001	TRIBOULEY	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	CJ	WO00/52028-A1	09/08/2000	HUMAN GENOME SCIENCES, INC.		
	CK	WO01/22920-A2	04/05/2001	HUMAN GENOME SCIENCES, INC.	pages 1-11, 28, 309-334, 358-408, 545-6, 1769 to 2227 and SEQ ID NOS: 227 and 4504	
	CL	WO01/28582-A3	04/26/2001	ELI LILLY AND COMPANY		
	CM	WO01/42463-A1	06/14/2001	ELI LILLY AND COMPANY		
	CN	WO01/42434-A1	06/14/2001	MERCK & CO., INC.		
	CO	WO01/68912-A3	09/20/2001	EPIGENOMICS AG		
	CP	WO02/00677-A1	01/03/2002	HUMAN GENOME SCIENCES, INC.	pages 1-16, 950- 957, 1480-1483, 1604, 1716-1726, 2377, 2401- end of specification; and SEQ ID NOS: 937 and 3112	
	CQ	WO02/000928-A3	01/03/2002	EPIGENOMICS AG	Abstract & Int'l Search Report	
	CR	WO02/09668-A2	02/07/2002	ELI LILLY AND COMPANY		
	CS	WO02/060317-A2	08/08/2002	CORIXA CORPORATION		
	CT	WO02/060947-A3	08/08/2002	ELI LILLY AND COMPANY		
	CU	WO02/060949-A3	08/08/2002	ELI LILLY AND COMPANY		
	CV	WO02/078524-A2	10/10/2002	ZYCOS, INC.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/518,931-Conf. #7173
				Filing Date	March 3, 2000
				First Named Inventor	Reiner L. Gentz
				Art Unit	1646
				Examiner Name	E. B. O'Hara
Sheet	3	of	3	Attorney Docket Number	PF454P1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CW	YU et al., GenBank Accession No. AF134240, May 11, 1999.	
	CX	ASHKENAZI and DIXIT, "Apoptosis control by death and decoy receptors," Curr. Opin. Cell Biol. 11 (2), 255-260 (1999).	
	CZ	KIKUNO et al., PIR Accession No. T45294, January 31, 2000.	
	DA	BAI et al., GenBank Accession No. AF217793, February 12, 2000.	
	DB	BAI et al., GenBank Accession No. AF217794, February 12, 2000.	
	DC	BAI et al., GenBank Accession No. AF217796, February 21, 2000.	
	DD	YAN et al., "Two-Amino Acid Molecular Switch in an Epithelial Morphogen...", Science 290, 523-527, (October 20, 2000).	
	DE	OHSHIMA et al., "Amplification and expression of a decoy receptor for Fas ligand...", Cancer Letters 160, 89-97, (2000).	
	DF	LOCKSLEY et al., "The TNF and TNF Receptor Superfamilies: Integrating Mammalian Biology," Cell 104, 487-501, (February 23, 2001).	
	DG	WALLIS, GenBank Accession No. AL353715, April 18, 2001.	
	DH	MATTHEWS, GenBank Accession No. AL121845, July 6, 2001.	
	DI	PITTI et al., GenBank Accession No. NM 032945, July 6, 2001.	
	DJ	PITTI et al., GenBank Accession No. NM 032957, July 17, 2001.	
	DK	ADAMS et al., "Initial assessment of human gene diversity and expression patterns," Nature 377 (6547 Supp) 3-174, (September 28, 1995).	
	DL	ADAMS et al., Genbank Accession No. AA325843, April 20, 1997.	
	DM	HILLIER et al., GenBank Accession No. AA025672, February 1, 1997.	
	DN	HILLIER et al., GenBank Accession No. AA155646, November 8, 1997.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



Under the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control number.

Effective on 12/08/2004. Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).		Complete if Known	
FEE TRANSMITTAL For FY 2005		Application Number	09/518,931-Conf. #7173
		Filing Date	March 3, 2000
		First Named Inventor	Reiner L. Gentz
		Examiner Name	E. B. O'Hara
		Art Unit	1646
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27	Attorney Docket No.	PF454P1	
TOTAL AMOUNT OF PAYMENT		(\$) 180.00	

METHOD OF PAYMENT (check all that apply)	
<input type="checkbox"/> Check	<input type="checkbox"/> Credit Card
<input type="checkbox"/> Money Order	<input type="checkbox"/> None
<input type="checkbox"/> Other (please identify): _____	
<input checked="" type="checkbox"/> Deposit Account	Deposit Account Number: <u>08-3425</u> Deposit Account Name: <u>Human Genome Sciences, Inc.</u>
For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)	
<input checked="" type="checkbox"/> Charge fee(s) indicated below	<input type="checkbox"/> Charge fee(s) indicated below, except for the filing fee
<input checked="" type="checkbox"/> Charge any additional fee(s) or underpayment of fee(s) under 37 CFR 1.16 and 1.17	<input checked="" type="checkbox"/> Credit any overpayments

FEE CALCULATION							
1. BASIC FILING, SEARCH, AND EXAMINATION FEES							
	FILING FEES		SEARCH FEES		EXAMINATION FEES		
		Small Entity		Small Entity		Small Entity	
Application Type	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	Fees Paid (\$)
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	
2. EXCESS CLAIM FEES							
						Fee (\$)	Small Entity Fee (\$)
Fee Description							
Each claim over 20 (including Reissues)						50	25
Each independent claim over 3 (including Reissues)						200	100
Multiple dependent claims						360	180
Total Claims		Extra Claims	Fee (\$)	Fee Paid (\$)	Multiple Dependent Claims		
_____ - 20 = _____		x _____	= _____		Fee (\$)	Fee Paid (\$)	
Indep. Claims		Extra Claims	Fee (\$)	Fee Paid (\$)			
_____ - 3 = _____		x _____	= _____				
3. APPLICATION SIZE FEE							
If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).							
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof		Fee (\$)	Fee Paid (\$)		
_____ - 100 = _____	/50	_____ (round up to a whole number) x _____		= _____			
4. OTHER FEE(S)							
Non-English Specification, \$130 fee (no small entity discount)						Fees Paid (\$)	
Other (e.g., late filing surcharge): <u>1806 Submission of an Information Disclosure Statement</u>						<u>180.00</u>	

SUBMITTED BY			
Signature	<u>Michele Shannon</u>	Registration No. (Attorney/Agent)	47,075
Name (Print/Type)	Michele Shannon	Telephone	(301) 354-3930
		Date	October 11, 2005